Progress Toward a Staphylococcus aureus Vaccine
Open accessAbstract
High attack rates and the ability of Staphylococcus aureus to develop resistance to all antibiotics in medical practice heightens the urgency for vaccine development. S. aureus causes many disease syndromes, including invasive disease, pneumonia, and skin and soft tissue infections. It remains unclear whether a single vaccine could protect against all of these. Vaccine composition is also challenging. Active immunization with conjugated types 5 and 8 capsular polysaccharides, an iron scavenging protein, isdB, and passive immunization against clumping factor A and lipoteichoic acid have all proven unsuccessful in clinical trials. Many experts advocate an approach using multiple antigens and have suggested that the right combination of antigens has not yet been identified. Others advocate that a successful vaccine will require antigens that work by multiple immunologic mechanisms. Targeting staphylococcal protein A and stimulating the T-helper 17 lymphocyte pathway have each received recent attention as alternative approaches to vaccination in addition to the more traditional identification of opsonophagocytic antibodies. Many questions remain as to how to successfully formulate a successful vaccine and to whom it should be deployed.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Protective immunity in animal infection models does not always predict vaccine efficacy in humans.
“The recent termination of human clinical trials for a S. aureus IsdB-containing vaccine highlights that protective immunity in animal models of infection may not always correlate to vaccine efficacy in humans (Daum and Spellberg, 2012).”
From Iron in infection and immunity (2013) · cites this paper as Daum and Spellberg, 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Klevens, R. M. (2007) · JAMA · doi:10.1001/jama.298.15.1763 · Cited by 3,726 · see citing works
Waves of resistance: Staphylococcus aureus in the antibiotic era
Chambers, H. F., & DeLeo, F. R. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2200 · Cited by 2,718 · see citing works
David, M. Z., & Daum, R. S. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00081-09 · Cited by 1,972 · see citing works
Self-citationMiller, L. G., Perdreau-Remington, F., Rieg, G., Mehdi, S., Perlroth, J., Bayer, A. S., Tang, A. W., Phung, T. O., & Spellberg, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042683 · Cited by 1,053 · see citing works
Self-citationIshigame, H., Kakuta, S., Nagai, T., Kadoki, M., Nambu, A., Komiyama, Y., Fujikado, N., Tanahashi, Y., Akitsu, A., Kotaki, H., et al. (2009) · Immunity · doi:10.1016/j.immuni.2008.11.009 · Cited by 1,004 · see citing works
Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-09 · Cited by 962 · see citing works
Health Care–Associated Invasive MRSA Infections, 2005-2008
Kallen, A. J. (2010) · JAMA · doi:10.1001/jama.2010.1115 · Cited by 439 · see citing works
Kuklin, N. A., Clark, D. J., Secore, S., Cook, J., Cope, L. D., McNeely, T., Noble, L., Brown, M. J., Zorman, J. K., Wang, X. M., et al. (2006) · Infection and Immunity · doi:10.1128/iai.74.4.2215-2223.2006 · Cited by 264 · see citing works
Liu, C., Graber, C. J., Karr, M., Diep, B. A., Basuino, L., Schwartz, B. S., Enright, M. C., O’Hanlon, S. J., Thomas, J. C., Perdreau‐Remington, F., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/587893 · Cited by 205 · see citing works
Flagged first, then by citations
Research works printed but not linked: 41
- Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520-32.
- Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298:1763-1.
- Morrison-Rodriguez SM, Pacha LA, Patrick JE, Jordan NN. Community-associated methicillin-resistant Staphylococcus aureus infections at an Army training installation. Epidemiol Infect 2010; 138:721-9.
- Pe ´richon B, Courvalin P. VanA-type vancomycin-resistant Staphylococcus aureus. Antimicrob Agents Ch 2009; 53:4580-7.
- Locke JB, Hilgers M, Shaw KJ. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob Agents Ch 2009; 53:5265-74.
- Mendes RE, Deshpande LM, Castanheira M, DiPersio J, Saubolle MA, Jones RN. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob Agents Ch 2008; 52:2244-6.
- Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus stan- dard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-65.
- Cadilla A, David MZ, Daum RS, Boyle-Vavra S. Association of high-level mupirocin resistance and multidrug-resistant methicillin- resistant Staphylococcus aureus at an academic center in the Midwestern United States. J Clin Micro 2010; 49:95-100.
- Shinefield H, Black S, Fattom A, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002; 346:491-6.
- Shapiro CN, HS M. Hepatitis B epidemiology and prevention. Epidemiol Rev 1990; 12:221-7.
- Centers for Disease Control and Prevention. A Comprehensive immu- nization strategy to eliminate transmission of hepatitis B Virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of infants, chil- dren and adolescents. MMWR Recomm Rep 2005; 54:1-23.
- Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus-United States. MMWR Morb Mortal Wkly Rep 1981; 30:557-9.
- Lee CJ, Sankaran S, Mukherjee DV, et al. Staphylococcus aureus oro- pharyngeal carriage in a prison population. Clin Infect Dis 2011; 52:775-8.
- von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia: Study Group. N Engl J Med 2001; 344:11-6.
- Adem P, Montgomery C, Husain A, et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. New Engl J Med 2005; 353:1245-51.
- Mongkolrattanothai K, Boyle S, Kahana MD, Daum RS. Severe Staphylococcus aureus infections caused by clonally related community- acquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis 2003; 37:1050-8.
- Kravitz GR, Dries DJ, Peterson ML, Schlievert PM. Purpura fulminans due to Staphylococcus aureus. Clin Infect Dis 2005; 40:941-7.
- Gonzalez BE, Hulten KG, Dishop MK, et al. Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection. Clin Infect Dis 2005; 41:583-90.
- Bocchini CE, Hulten KG, Mason EO Jr, Gonzalez BE, Hammerman WA, Kaplan SL. Panton-Valentine leukocidin genes are associated with enhanced inflammatory response and local disease in acute hema- togenous Staphylococcus aureus osteomyelitis in children. Pediatrics 2006; 117:433-40.
- Verdier I, Durand G, Bes M, et al. Identification of the capsular poly- saccharides in Staphylococcus aureus clinical isolates by PCR and agglu- tination tests. 2007; 45:725-9.
- Montgomery CP, Boyle-Vavra S, Adem P, et al. Comparison of virulence in community-associated methicillin-resistant Staphylococcus aureus pul- sotypes USA300 and USA400 in a rat model of pneumonia. J Infect Dis 2008; 198:561-70.
- Maira-Litran T, Kropec A, Abeygunawardana C, et al. Immunochemical properties of the staphylococcal poly-N-acetylglucosamine surface polysaccharide. Infect Immun 2002; 70:4433-40.
- Cramton SE, Gerke C, Schnell NF, Nichols WW, Go ¨tz F. The intercellular adhesin (ica) locus is present in Staphylococcus aureus and required for biofilm formation. Infect Immun 1999; 67:5427-33.
- Heilman C, Schweitzer O, Gerke C, Schnell NF, Nichols WW, Go ¨tz F. Molecular basis of intercellular adhesion in the biofilm forming Staphy- lococcus epidermidis. Mol Microbiol 1996; 20:1083-91.
- Vuong C, Kocianova S, Voyich JM, et al. A crucial role for exopoly- saccharide modification in bacterial biofilm formation, immune evasion and virulence. J Biol Chem 2004; 279:54881-6.
- Cerca N, Jefferson K, Maira-Litran T, et al. Molecular basis for prefer- ential protective efficacy of antibodies directed to the poorly acetylated form of staphylococcal poly-N-acetyl-beta-(1-6)-glucosamine. Infect Immun 2007; 75:3401-13.
- Kelly-Quintos C, Kropec A, Briggs S, Ordonez CL, Goldmann DA, Pier GB. The role of epitope specificity in the human opsonic antibody response to the staphylococcal surface polysaccharide poly N-acetyl glucosamine. J Infect Dis 2005; 192:2012-9.
- Maira-Litran T, Kropec A, Goldmann DA, Pier GB. Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines con- taining native or deacetylated staphylococcal poly-N-acetyl-beta-(1-6)- glucosamine. Infect Immun 2005; 73:6752-62.
- Kaufman D. Veronate (Inhibitex). Curr Opin Investig Drugs 2006; 7:172-9.
- Brown EL, Dumitrescu O, Thomas D, et al. The Panton-Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300. Clin Microbiol Infec 2009; 15:156-64.
- Bubeck Wardenburg J, Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 2008; 205:287-94.
- Stranger-Jones YK, Bae T, Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci USA 2006; 103:16942-7.
- Goodyear CS, Silverman GJ. B cell superantigens: a microbe's answer to innate-like B cells and natural antibodies. Springer Sem Immun 2005; 26:463-84.
- Kim HK, Cheng AG, Kim HY, Missiakas DM, Schneewind O. Non- toxigenic protein A vaccine for methicillin-resistant Staphylococcus aureus infections in mice. J Exp Med 2010; 207:1863-70.
- Spellberg B, Ibrahim AS, Yeaman MR, et al. The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus. Infect Immun 2008; 76:4574-80.
- Lin L, Ibrahim AS, Baquir B, Avanesian V, Fu Y, Spellberg B. Immu- nological surrogate marker of rAls3p-N vaccine-induced protection against Staphylococcus aureus. FEMS Immunol Med Mic 2009; 55:293-5. Epub 2009 Jan 13.
- Lin L, Ibrahim AS, Xu X, et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 2009; 5:e1000703.
- Cho JS, Pietras EM, Garcia NC, et al. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest 2010; 120:1762-3.
- Pachl J, Svoboda P, Jacobs F, et al. Mycograb Invasive Candidiasis Study Group: A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006; 42:1404-13.
- Torosantucci A, Bromuro C, Chiani P, et al. A novel glyco- conjugate vaccine against fungal pathogens. J Exp Med 2005; 202: 597-606.
- Torosantucci A, Chiani P, Bromuro C, et al. Protection by anti-beta- glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS One 2009; 4:e5392 Epub 2009 Apr 28.
Cited by
Sorted by citations
Iron in infection and immunity
Cassat, J. E., & Skaar, E. P. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.04.010 · Cited by 1,214 · see citing works
Where does a Staphylococcus aureus vaccine stand?
Fowler, V. G., & Proctor, R. A. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12570 · Cited by 241 · see citing works
Magnetic Nanoparticle Targeted Hyperthermia of Cutaneous Staphylococcus aureus Infection
Kim, M.-H., Yamayoshi, I., Mathew, S., Lin, H., Nayfach, J., & Simon, S. I. (2013) · Annals of Biomedical Engineering · doi:10.1007/s10439-012-0698-x · Cited by 135 · see citing works
- Authors
- Daum, R. S., & Spellberg, B.
- Affiliations
- University of Chicago Medical Center (US)
- University of California, Los Angeles (US)
- ORCID
- Spellberg, B.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-12-20
- Volume
- 54
- Issue
- 4
- Pages
- 560-567
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC3404717
- OpenAlex
- W2110481642
- Cited by
- 165
- References
- 9
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 3 · 2023: 9 · 2022: 5 · 2021: 8 · 2020: 4 · 2019: 13 · 2018: 10 · 2017: 11 · 2016: 18 · 2015: 18 · 2014: 19 · 2013: 25 · 2012: 15
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- University of Chicago
- Medicines Company
- Eisai
- Astellas Pharma
- Centers for Disease Control and Prevention (R01CI000373, U01CI000384)
- Sanofi Pasteur
- National Institute of Allergy and Infectious Diseases (R01AI40481, R01AI067584, R01AI072052, R01AI040481)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- Staphylococcus aureus, vaccine development, ISDB, clumping factor A, lipoteichoic acid, protein A, antibiotic resistance, skin and soft tissue infections, pneumonia
- MeSH terms
- Antigens, Bacterial, Humans, Staphylococcal Infections, Staphylococcal Vaccines, Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
